Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30344% above fair value
$14.80+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
Personalis price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Personalis's price to sales ratio was 24.4× on Nov 11, 2026, against 13.8× a year earlier. Over the last 5 years it ranged from 0.7× to 25.6×, with a median of 3.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 24.4× | +14.1 |
| 2025 | Dec 31, 2025 | 10.2× | +5.6 |
| 2024 | Dec 31, 2024 | 4.7× | +3.2 |
| 2023 | Dec 29, 2023 | 1.5× | +0.1 |
| 2022 | Dec 30, 2022 | 1.3× | −6.2 |
| 2021 | Dec 31, 2021 | 7.5× | −11.0 |
| 2020 | Dec 31, 2020 | 18.5× | +12.9 |
| 2019 | Dec 31, 2019 | 5.6× | – |
See a number that looks wrong?